Deacon Biosciences, Inc. Report issue

For profit Phase 2
Founded: New York NY United States (2000)
Status: Acquired by ICON (2009)

Organization Overview

First Clinical Trial
2013
NCT01853722
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

dcn01 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Eye Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1